WASHINGTON -- -- When a major medical journal raised questions about heart risks from a leading diabetes drug earlier this year, many patients began avoiding the drug. But concern turned to dismay when news emerged that both the Food and Drug Administration and the manufacturer had also picked up worrisome signals about the drug -- but had not sounded an alarm, pending further study.
